Amarin Corp - ADR

NASDAQ:AMRN  
1.42
-0.02 (-1.39%)
Other Pre-Announcement

Amarin Reports First Quarter 2022 Financial Results

Published: 05/04/2022 13:41 GMT
Amarin Corp - ADR (AMRN) - Amarin Reports First Quarter 2022 Financial Results and Provides Business Update.
Plans for Regulatory Filings for Approval of Vascepa® (icosapent Ethyl) in Several Additional Countries in 2022.
Total Net Revenue for Q1 Ended March 31, 2022 Was $94.6 Million, Compared to $142.2 Million in Corresponding Period of 2021.
Qtrly Diluted Loss per Share of $0.08.
Amarin Will Continue to Suspend 2022 Revenue Guidance.
In 2022 U.S. Commercial Operations Are Expected to Continue to Operate on a Contribution Margin Positive Basis.company Will Continue to Evaluate Its Planned Operational Spend in 2022 and Adjust If Assumptions Warrant It.
Reiterates Its Belief That Current Cash and Investments and Other Assets Are Adequate to Support Continued Operations in 2022.
Q1 Earnings per Share View $-0.02, Revenue View $128.4 Million -- Refinitiv Ibes Data (analyst estimates).